ecropolis

Low Risk of Severe Acute Respiratory Syndrome Coronavirus 2 Transmission by Fomites: A Clinical Observational Study in Highly Infectious Coronavirus Disease 2019 | Nucleocapsid Antigenemia Is a Marker of Acute SARS-CoV-2 Infection | Imprinted SARS-CoV-2 humoral immunity induces convergent Omicron RBD evolution | Can SARS-CoV-2 trigger new onset of autoimmune disease in adults? A case-based review | Protection against Omicron from Vaccination and Previous Infection in a Prison System | Nirmatrelvir and the Risk of Post-Acute Sequelae of COVID-19

Severe Monkeypox in Hospitalized Patients — United States, August 10–October 10, 2022 | Reinfections with Different SARS-CoV-2 Omicron Subvariants, France (CDC) | In adults with COVID-19, melatonin was assessed for effects on inflammatory markers, clinical signs and symptoms, and mortality | Influenza Incidence and Vaccine Effectiveness During the Southern Hemisphere Influenza Season — Chile, 2022 | Nirsevimab for Prevention of RSV in Healthy Late-Preterm and Term Infants | Unadjuvanted intranasal spike vaccine elicits protective mucosal immunity against sarbecoviruses

Progress Toward Poliomyelitis Eradication — Pakistan, January 2021–July 2022 | Polio by the Numbers—A Global Perspective | Phase 1/2a Safety and Immunogenicity of an Adenovirus 26 Vector RSV Vaccine Encoding Prefusion F in Adults 18–50 Years and RSV Seropositive Children 12–24 Months | Receipt of First and Second Doses of JYNNEOS Vaccine for Prevention of Monkeypox — United States, May 22–October 10, 2022 | Novavax NVX-COV2373 triggers potent neutralization of Omicron sub-lineages

A healthcare-associated infection with Monkeypox virus of a healthcare worker during the 2022 outbreak | Tolerability and immunogenicity of an intranasally-administered adenovirus-vectored COVID-19 vaccine: An open-label partially-randomized ascending dose phase I trial | Clinical, Virologic, and Immunologic Evaluation of Symptomatic Coronavirus Disease 2019 Rebound Following Nirmatrelvir/Ritonavir Treatment | Early outpatient treatment with remdesivir in patients at high risk for severe COVID-19: a prospective cohort study